178 related articles for article (PubMed ID: 30952968)
1. A Tumor-Selective Monoclonal Antibody from Immunization with a Tumor-Associated Mucin Glycopeptide.
Trabbic KR; Whalen K; Abarca-Heideman K; Xia L; Temme JS; Edmondson EF; Gildersleeve JC; Barchi JJ
Sci Rep; 2019 Apr; 9(1):5662. PubMed ID: 30952968
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction directed against the tumor-associated MUC4 glycoprotein.
Cai H; Palitzsch B; Hartmann S; Stergiou N; Kunz H; Schmitt E; Westerlind U
Chembiochem; 2015 Apr; 16(6):959-67. PubMed ID: 25755023
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer.
Jain M; Venkatraman G; Moniaux N; Kaur S; Kumar S; Chakraborty S; Varshney GC; Batra SK
PLoS One; 2011; 6(8):e23344. PubMed ID: 21886786
[TBL] [Abstract][Full Text] [Related]
5. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
Hanisch FG; Stadie T; Bosslet K
Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
[TBL] [Abstract][Full Text] [Related]
7. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
8. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
9. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
[TBL] [Abstract][Full Text] [Related]
10. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans.
Moniaux N; Varshney GC; Chauhan SC; Copin MC; Jain M; Wittel UA; Andrianifahanana M; Aubert JP; Batra SK
J Histochem Cytochem; 2004 Feb; 52(2):253-61. PubMed ID: 14729877
[TBL] [Abstract][Full Text] [Related]
12. Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.
Heimburg-Molinaro J; Almogren A; Morey S; Glinskii OV; Roy R; Wilding GE; Cheng RP; Glinsky VV; Rittenhouse-Olson K
Neoplasia; 2009 Aug; 11(8):780-92. PubMed ID: 19649208
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.
Xu Y; Sette A; Sidney J; Gendler SJ; Franco A
Immunol Cell Biol; 2005 Aug; 83(4):440-8. PubMed ID: 16033540
[TBL] [Abstract][Full Text] [Related]
14. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.
Brinãs RP; Sundgren A; Sahoo P; Morey S; Rittenhouse-Olson K; Wilding GE; Deng W; Barchi JJ
Bioconjug Chem; 2012 Aug; 23(8):1513-23. PubMed ID: 22812418
[TBL] [Abstract][Full Text] [Related]
16. Influence of terminal residue on adjacent disaccharide immunogenicity.
Irazoqui FJ; Lopez PH; Mandel U; Nores GA
Mol Immunol; 2002 Mar; 38(11):825-31. PubMed ID: 11922940
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
18. Production of mouse monoclonal anti-idiotypic antibodies specific to epitopes of tumor-associated mucin TAG-12.
Schmitt H; Khazaeli MB; Rodenburg CM; Kaul S; Bastert G
Hybridoma; 1994 Oct; 13(5):389-96. PubMed ID: 7532153
[TBL] [Abstract][Full Text] [Related]
19. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
[TBL] [Abstract][Full Text] [Related]
20. Short synthetic glycopeptides successfully induce antibody responses to carcinoma-associated Tn antigen.
Vichier-Guerre S; Lo-Man R; Bay S; Deriaud E; Nakada H; Leclerc C; Cantacuzène D
J Pept Res; 2000 Feb; 55(2):173-80. PubMed ID: 10784033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
